International: +1-347-960-6455
Mycoses Therapeutics - Pipeline Analysis 2018

Mycoses Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10068 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Mycoses, also known as fungal infections are categorized into different types based on their invasiveness. The different types of mycoses are superficial, cutaneous, subcutaneous, dimorphic systemic, and opportunistic systemic mycoses. Superficial mycoses cause fungal infections of the skin or hair shaft. Superficial infections of the epidermis, hair, and nails are called cutaneous mycoses. Mycoses that penetrate in epidermis and dermis to infect deeper tissues are called subcutaneous mycoses. Mycoses that spread throughout the body are called systemic mycoses. Dimorphic systemic mycoses are fungal infections caused by fungal pathogens which can overcome the defenses of the normal human host, by changing their morphological form. Opportunistic systemic mycoses are fungal infections which occur almost exclusively in debilitated patients, whose normal defense mechanisms are impaired. Matinas BioPharma Holdings Inc., AlgiPharma AS, and Amplyx Pharmaceuticals Inc. are among the few players involved in the pipeline of mycoses.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.